BioNTech SE (BNTX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$95.26
Price Target
$137.13
Target Range
$113.00 — $155.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-18.0x
Forward PEG—
Implied Growth+4.0%
Median Target$139.00
Analyst Spread30.6%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$113
+18.6%
Consensus
$137
+44.0%
Bull Case
$155
+62.7%
BNTX Price Target Analysis
Updated May 7, 2026As of May 7, 2026, BioNTech SE (BNTX) has a Wall Street consensus price target of $137.13, based on estimates from 24 covering analysts. With the stock currently trading at $95.26, this represents a potential upside of +44.0%. The company has a market capitalization of $23.94B.
Analyst price targets range from a low of $113.00 to a high of $155.00, representing a 31% spread in expectations. The median target of $139.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 20 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BNTX trades at a trailing P/E of -18.0x. Analysts expect EPS to grow +4.0% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+45.3%
Avg Forward P/E21.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MRNAModerna, Inc. | $19.3B | $48.79 | $36.00 | -26.2% | Hold | — | 27 |
 PFEPfizer Inc. | $150.8B | $26.50 | $27.27 | +2.9% | Hold | 9.0x | 39 |
 NVAXNovavax, Inc. | $1.5B | $9.36 | $18.00 | +92.3% | Buy | — | 23 |
 ARCTArcturus Therapeutics Holdings Inc. | $260M | $9.13 | $22.50 | +146.4% | Buy | — | 21 |
 REGNRegeneron Pharmaceuticals, Inc. | $74.9B | $720.78 | $865.68 | +20.1% | Buy | 15.6x | 48 |
 VRTXVertex Pharmaceuticals Incorporated | $108.8B | $427.65 | $552.27 | +29.1% | Buy | 22.3x | 56 |
 BMRNBioMarin Pharmaceutical Inc. | $10.5B | $54.60 | $89.64 | +64.2% | Buy | 12.7x | 41 |
 ALNYAlnylam Pharmaceuticals, Inc. | $40.4B | $303.00 | $445.67 | +47.1% | Buy | 45.2x | 52 |
 BEAMBeam Therapeutics Inc. | $3.3B | $32.33 | $40.83 | +26.3% | Buy | — | 27 |
 NTLAIntellia Therapeutics, Inc. | $1.6B | $13.85 | $20.88 | +50.8% | Buy | — | 39 |
Upside Potential Comparison
ARCTNVAXBMRNNTLAALNYVRTXBEAMREGNFull BNTX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BNTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BNTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BNTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBNTX — Frequently Asked Questions
Quick answers to the most common questions about buying BNTX stock.
What is the BNTX stock price target for 2026?
The consensus Wall Street price target for BNTX is $137.13, representing 44.0% upside from the current price of $95.26. With 24 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is BNTX a buy, sell, or hold?
BNTX has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is predominantly bullish, with 20 Buy/Strong Buy ratings. The consensus 12-month price target of $137.13 implies 44.0% upside from current levels.
Is BNTX stock overvalued or undervalued?
BNTX's current price is $95.26 with a consensus target of $137.13 (44.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can BNTX stock go?
The most bullish Wall Street analyst has a price target of $155 for BNTX, while the most conservative target is $113. The consensus of $137.13 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover BNTX stock?
BNTX is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 20 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BNTX stock forecast?
The 12-month BNTX stock forecast based on 24 Wall Street analysts shows a consensus price target of $137.13, with estimates ranging from $113 (bear case) to $155 (bull case). The median consensus rating is "Buy".
Should I buy BNTX stock?
Wall Street analysts are very optimistic on BNTX, with a "Buy" consensus rating and $137.13 price target (44.0% upside). 20 of 24 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BNTX price targets vary so much?
BNTX analyst price targets range from $113 to $155, a 31% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $137.13 consensus represents the middle ground.